Market Overview

Ariad Pharnaceuticals Continues To Rally

Related ARIA
Cowen: In Biotech Earnings We Trust
Benzinga's Top #PreMarket Losers

Following a BMO Capital upgrade to Outperform and price target raised to $14, Ariad Pharmaceuticals (NASDAQ: ARIA) shares are 20% percent higher in Friday's trading at 9.24. Earlier in the session, the issue traded as high as 9.83. That is the highest level for ARIA since it cascaded from 17.14 on October 8, 2013.

Posted-In: Movers & Shakers Technicals Intraday Update Trading Ideas General


Related Articles (ARIA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters